Beijing: Cansino Biologist Inc.
(Cansinobio) Covid-19 single dose vaccine, is given at a lower dose than that for adults, safe and triggering immune response in children aged 6-17, the results of small trial shows.
The researcher decided to reduce the dose after several participants developed fever and headaches were considered at the second lowest severity of four levels.
In children, a lower dose triggers a higher level of antibodies than the approved dosage for use in adults in China, according to additional data reviewed by peer-reviewed from the middle stage trial.
The trial recruited 150 children and around 300 adults.
The results also show that children who are given a lower dose have a stronger antibody response than adults who are given a booster shooting 56 days after the first dose.
But the reading of antibodies does not show the extent to which vaccines can offer protection against Covid-19, researchers from the Board of China’s Disease Control Agency, Cansinobio and other Chinese institutions are warned in a paper.
Cansinobio vaccine hasn’t got a green light for children.
China has approved two vaccines, developed by Sinovac and Sinopharm, to be used in children from the age of three but vaccinations have not started for those under 12.
The newspaper said the driving shot for the Cansinobio vaccine improved the participant’s antibody response from the age group different, especially for older adults.
But cellular responses, other important parts of the human immune system, were not driven by the second shot and the researchers said the interval that was broader than 56 days must be considered.